| Contributors |
|
xi | |
| Introduction |
|
xv | |
|
1 Amniotic Fluid Stem Cells |
|
|
1 | (16) |
|
|
|
|
|
|
|
1 | (1) |
|
Development of Gestational Stem Cells |
|
|
2 | (1) |
|
Isolation and Characterization of Amniotic Fluid Stem Cells |
|
|
2 | (1) |
|
Multipotency of Amniotic Fluid Stem Cells |
|
|
3 | (5) |
|
Clinical Application of Amniotic Fluid Stem Cells |
|
|
8 | (5) |
|
|
|
13 | (1) |
|
|
|
13 | (4) |
|
2 Cord Blood Transplants: Perinatal Stem Cells in Clinical Practice |
|
|
17 | (20) |
|
|
|
|
|
|
|
17 | (1) |
|
Hematopoietic Stem Cell Transplants: Adult Donor Collection |
|
|
17 | (1) |
|
Hematopoietic Stem Cell Transplants: HLA Matching |
|
|
18 | (1) |
|
Collection and Processing of Cord Blood Units |
|
|
19 | (1) |
|
Hematopoietic Stem Cell Transplants: Recipient Issues |
|
|
20 | (1) |
|
Bone Marrow versus Single Cord Blood: Pediatric |
|
|
21 | (2) |
|
Bone Marrow versus Cord Blood: Adults |
|
|
23 | (1) |
|
Cord Blood Transplant: Advantages and Disadvantages |
|
|
23 | (1) |
|
Double Cord Blood Transplants: Ablative Regimens |
|
|
24 | (2) |
|
Double Cord Blood Transplant: Non-Myeloablative Regimens |
|
|
26 | (1) |
|
Are Two Cords Better Than One? |
|
|
27 | (1) |
|
|
|
28 | (1) |
|
|
|
28 | (2) |
|
Other Experimental Strategies |
|
|
30 | (1) |
|
|
|
31 | (1) |
|
|
|
31 | (6) |
|
3 Hematopoietic Stem Cell Development in the Placenta |
|
|
37 | (16) |
|
|
|
|
|
|
|
|
|
37 | (1) |
|
|
|
37 | (1) |
|
Historical Perspective on Placental Hematopoiesis |
|
|
38 | (1) |
|
The Development and Structure of the Mouse Placenta |
|
|
39 | (1) |
|
Hematopoietic Activity in the Mouse Placenta |
|
|
40 | (2) |
|
Identification of Placental HSCs |
|
|
42 | (1) |
|
The Origin and Localization of Placental HSCs |
|
|
43 | (2) |
|
Hematopoietic Activity in the Human Placenta |
|
|
45 | (1) |
|
Hematopoietic Microenvironment in the Placenta |
|
|
46 | (1) |
|
Conclusions and Perspectives |
|
|
47 | (2) |
|
|
|
49 | (4) |
|
4 Perinatal Mesenchymal Stem Cell Banking for Umbilical Cord Blood Transplantation and Regenerative Medicine |
|
|
53 | (18) |
|
|
|
|
|
53 | (1) |
|
|
|
54 | (1) |
|
Hematopoietic Transplantations |
|
|
54 | (2) |
|
Umbilical Cord: Source of Perinatal HSCs and MSCs |
|
|
56 | (1) |
|
Hematopoietic Transplantations of Umbilical Cord Blood |
|
|
57 | (1) |
|
Strategies to Overcome the Transplant-Related Limitations of Umbilical Cord Blood |
|
|
58 | (3) |
|
Umbilical Cord Tissue MSC Banking |
|
|
61 | (2) |
|
|
|
63 | (8) |
|
5 Making Organ and Stem Cell Transplantation Safer: The Role of Mesenchymal Stem Cells |
|
|
71 | (6) |
|
|
|
|
|
71 | (1) |
|
MSC to Prevent Rejection After Solid Organ Transplantation |
|
|
72 | (1) |
|
MSC in the Treatment of Graft-versus-Host Disease |
|
|
73 | (1) |
|
MSC to Support Hematopoietic Recovery of Stem Cells After Stem Cell Transplantation |
|
|
74 | (1) |
|
|
|
75 | (2) |
|
6 Wharton's Jelly Mesenchymal Stem Cells and Immune Modulation: Regenerative Medicine Meets Tissue Repair |
|
|
77 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77 | (2) |
|
Expression of Relevant Immunomodulatory Molecules in Vitro by MSCs |
|
|
79 | (1) |
|
Tolerance Induction by MSCs: Rediscovering the Embryo Immune Evasion Mechanisms |
|
|
79 | (1) |
|
Immune Modulation in Vivo: Contrasting Data on the Immune Privilege of MSCs |
|
|
80 | (2) |
|
WJ-MSC in in Vivo Models: Enhancing the Immunomodulatory Features of Adult MSC Populations |
|
|
82 | (1) |
|
Conclusions and Future Perspectives |
|
|
83 | (1) |
|
|
|
84 | (5) |
|
7 Immunogenicity Versus Immunomodulation of Perinatal Stem Cells |
|
|
89 | (16) |
|
|
|
|
|
|
|
89 | (1) |
|
Mechanisms of Immunomodulation by Umbilical Cord- and Bone Marrow-Derived MSCs |
|
|
90 | (1) |
|
|
|
90 | (2) |
|
|
|
92 | (2) |
|
Natural Tolerance and Umbilical Cord Tissues |
|
|
94 | (1) |
|
Tolerance versus Immunogenicity: The Yin and Yang of Host Responses to Umbilical Cord-Derived Cells |
|
|
95 | (2) |
|
|
|
97 | (1) |
|
|
|
98 | (7) |
|
8 The Translational Potential of Perinatal Stem Cells in Clinical Medicine: Mesenchymal Stem Cells |
|
|
105 | (14) |
|
|
|
|
|
|
|
|
|
|
|
105 | (1) |
|
Graft-versus-Host Disease |
|
|
106 | (1) |
|
|
|
107 | (1) |
|
|
|
108 | (1) |
|
|
|
109 | (1) |
|
Hematopoetic Recovery and HCT Engraftment |
|
|
109 | (1) |
|
|
|
110 | (1) |
|
|
|
111 | (1) |
|
|
|
111 | (2) |
|
|
|
113 | (6) |
|
9 Newborn Stem Cells: Identity, Function, and Clinical Potential |
|
|
119 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
120 | (1) |
|
The Newborn Offers an Enormous Opportunity for Stem Cells |
|
|
120 | (1) |
|
|
|
120 | (1) |
|
Isolation and Phenotypic Characterization of Amnion Cells |
|
|
121 | (2) |
|
Therapeutic Potential of Amnion Membrane |
|
|
123 | (2) |
|
Mechanisms of AEC-Enhanced Wound Repair |
|
|
125 | (2) |
|
Therapeutic Potential of Amnion as Single Cells |
|
|
127 | (1) |
|
Amnion Immunogenicity and Immunosuppressive Properties |
|
|
127 | (1) |
|
Amnion-Derived Mesenchymal Stromal Cells |
|
|
128 | (2) |
|
Umbilical Cord Mesenchymal Stromal Cells |
|
|
130 | (1) |
|
|
|
131 | (2) |
|
|
|
133 | (6) |
|
10 Biomedical Potential of Human Perinatal Stem Cells |
|
|
139 | (16) |
|
|
|
|
|
Role of Stem Cells in Regenerative Medicine |
|
|
139 | (1) |
|
Perinatal Stem Cell Sources |
|
|
140 | (3) |
|
Properties of Perinatal Mesenchymal Stem Cells |
|
|
143 | (1) |
|
Properties of Perinatal Hematopoietic Stem Cells |
|
|
144 | (1) |
|
Biomedical Applications of Human Perinatal Stem Cells |
|
|
145 | (2) |
|
Perspectives and Obstacles |
|
|
147 | (1) |
|
|
|
148 | (7) |
|
11 Progenitor Cell Therapy for the Treatment of Traumatic Brain Injury |
|
|
155 | (22) |
|
|
|
|
|
|
|
|
|
|
|
155 | (4) |
|
Cellular Therapy for the Treatment of TBI |
|
|
159 | (1) |
|
Neural Stem Progenitor Cells |
|
|
159 | (1) |
|
Human Multipotent Adult Progenitor Cells |
|
|
160 | (3) |
|
|
|
163 | (2) |
|
|
|
165 | (1) |
|
|
|
166 | (1) |
|
Amniotic Fluid-Derived Stem Cells |
|
|
167 | (1) |
|
|
|
168 | (2) |
|
|
|
170 | (1) |
|
|
|
171 | (6) |
|
12 The Human Amniotic Membrane: A Tissue with Multifaceted Properties and Different Potential Clinical Applications |
|
|
177 | (20) |
|
|
|
|
|
|
|
|
|
177 | (1) |
|
Structure and Histology of the Human Amniotic Membrane |
|
|
178 | (1) |
|
Preparation, Preservation, and Sterilization of the Human Amniotic Membrane |
|
|
179 | (1) |
|
Biological and Structural Properties of the Human Amniotic Membrane Generally Invoked to Explain Its Effects in Vivo |
|
|
180 | (3) |
|
Established Clinical Applications of the Human Amniotic Membrane |
|
|
183 | (4) |
|
Prospective Applications of the Human Amniotic Membrane: Lessons from Preclinical Studies |
|
|
187 | (3) |
|
Conclusions and Perspectives |
|
|
190 | (1) |
|
|
|
190 | (7) |
|
13 Advances and Possible Applications of Human Amnion for the Management of Liver Disease |
|
|
197 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
197 | (1) |
|
Human Amnion for the Management of Liver Fibrosis |
|
|
198 | (1) |
|
Amnion-Derived Hepatocytes and Their Possible Applications |
|
|
199 | (5) |
|
|
|
204 | (1) |
|
|
|
205 | (4) |
|
14 Amnion-Derived Cells for Stroke Restorative Therapy |
|
|
209 | (12) |
|
|
|
|
|
|
|
|
|
209 | (1) |
|
Stem Cell Therapy: Beyond Stroke Neuroprotection |
|
|
210 | (1) |
|
Therapeutic Potential of Adult Stem Cells |
|
|
210 | (1) |
|
The Biology of Amnion-Derived Cells |
|
|
211 | (1) |
|
Amnion-Derived Cells for Cell Therapy |
|
|
212 | (3) |
|
|
|
215 | (1) |
|
|
|
216 | (5) |
|
15 Pregnancy-Acquired Fetal Progenitors as Natural Cell Therapy |
|
|
221 | (16) |
|
|
|
|
|
|
|
|
|
221 | (1) |
|
Fetal Cell Microchimerism, a Widespread Phenomenon |
|
|
222 | (1) |
|
The Kinetics of Fetal Cell Detection |
|
|
222 | (1) |
|
Factors Modifying the Level of Microchimerism |
|
|
222 | (1) |
|
|
|
223 | (1) |
|
Homing and Plasticity of FMC |
|
|
224 | (1) |
|
Hematopoietic Capacity of FMC |
|
|
224 | (4) |
|
Epithelial, Neuronal and Hepatic Capacity of FMC |
|
|
228 | (1) |
|
Mesenchymal Capacity of FMC |
|
|
228 | (1) |
|
FMC Includes Functional Endothelial Progenitor Cells that Contribute to Tissue Repair |
|
|
229 | (1) |
|
FMC Likely Includes Cells of Placental Origin |
|
|
230 | (1) |
|
|
|
230 | (1) |
|
|
|
231 | (4) |
|
|
|
235 | (2) |
|
16 Perinatal Stem Cells: An Industry Perspective |
|
|
237 | (12) |
|
|
|
|
|
237 | (1) |
|
The Public Cord Blood Banking Industry |
|
|
238 | (1) |
|
The Private Banking Industry |
|
|
239 | (1) |
|
Research and Cord Blood Clinical Trials |
|
|
240 | (1) |
|
The Mesenchymal Stem Cell Regenerative Medicine Industry |
|
|
241 | (1) |
|
Wharton's Jelly/Cord Tissue |
|
|
242 | (1) |
|
Placental Stem Cells and Placental Tissue |
|
|
243 | (1) |
|
|
|
244 | (1) |
|
|
|
245 | (1) |
|
|
|
245 | (4) |
|
17 Patent Protection of Stem Cell Innovations |
|
|
249 | (10) |
|
|
|
The Role of Patents in Commercialization |
|
|
249 | (1) |
|
Background of the Patent System |
|
|
250 | (1) |
|
Patentable Subject Matter |
|
|
251 | (1) |
|
Statutory Requirements for a Patent |
|
|
252 | (2) |
|
Written Description/Enablement/Best Mode |
|
|
254 | (2) |
|
|
|
256 | (3) |
|
18 Interview with Frances Verter, Founder of Parent's Guide to Cord Blood Foundation |
|
|
259 | (12) |
|
|
|
|
|
|
|
269 | (2) |
|
19 Umbilical Cord Blood Banking: An Obstetrician's Perspective |
|
|
271 | (8) |
|
|
|
|
|
277 | (2) |
| Index |
|
279 | |